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Glioblastoma Multiforme (GBM), the most common primary brain tumor in adults, has a median sur-
vival rate of 12 months, even with aggressive resection and radiation therapy (Fig. 1A). Regrettably, 
outcomes for this disease have not substantially improved since the Brain Tumor Study Group published 
their results over 25 years ago. The current standard of care for GBM consists of surgery followed by 
adjuvant radiotherapy. Although numerous phase III trials have attempted to demonstrate the beneﬁ  t of 
employing chemotherapy in these patients, either concomitantly with radiotherapy or as isolated adju-
vant treatment, a signiﬁ  cant prolongation of survival has never been documented.
Stupp and colleagues investigated the use of temozolomide (Fig. 1B) as an adjuvant to radiotherapy 
in patients with GBM and recently published their ﬁ  ndings in The New England Journal of Medicine 
(1). In this multi-institutional randomized clinical trial, 573 patients with newly diagnosed, histologi-
cally conﬁ  rmed GBM received either radiotherapy alone or radiotherapy plus concomitant temozolomide. 
Results demonstrated a median overall survival of 14.6 months (95% CI 13.2–16.8) for patients treated 
with radiotherapy and chemotherapy, compared to 12.1 months (95% CI 11.2–13.0) for those treated 
with radiotherapy alone. More importantly, the two-year survival rate was 26.5 percent (95% CI 
21.2–31.7) for patients treated with radiotherapy and chemotherapy, compared to only 10.4 percent 
(95% CI 6.8–14.1) for those treated with radiotherapy alone. The calculated hazard ratio for death in 
the radiotherapy-plus-temozolomide group was 0.63 (p  0.001). Of note, only 7 percent of patients 
receiving concomitant chemotherapy experienced grade III/IV hematologic toxic effects. Based on 
these ﬁ  ndings, the authors concluded that the addition of temozolomide to radiotherapy for GBM leads 
to survival beneﬁ  ts that are both clinically and statistically signiﬁ  cant with minimal additional toxicity. 
It is important to note, however, that patients with poor preoperative neurological status undergoing 
biopsy only are unlikely to beneﬁ  t. Moreover, it remains unclear whether the addition of chemotherapy 
increases the risk of radiation induced cognitive deﬁ  cits.
In the same issue of The New England Journal of Medicine, Hegi and colleagues investigated the 
relationship between promoter methylation of the MGMT DNA-repair gene and responsiveness to 
temozolomide (2). The authors demonstrated that the survival beneﬁ  t of temozolomide is limited to 
those patients with tumor containing methylated MGMT promoters. Among these patients, the median 
survival with radiotherapy and temozolomide was 21.7 months (95% CI 17.4–30.4), compared to 15.3 
months with radiotherapy alone (95% CI 13.0–20.9; p = 0.007). An insigniﬁ  cant survival difference 
was demonstrated between treatment groups in patients with unmethylated MGMT promoters. This 
ﬁ  nding points to a genetic basis for the efﬁ  cacy of temozolomide and underscores the role of gene 
expression in optimal patient selection.
Although these articles represent a substantial step forward in the treatment of GBM, at this point it 
is too early in standard clinical practice to choose treatment according to molecular criteria alone. It is 
also important to remember that several factors likely contributed the studies’ ﬁ  ndings. First, the major-
ity of patients was otherwise healthy and had favorable prognostic variables—age less than 70 years, 
good performance status, and tumor debulkment. Second, temozolomide is an alkylating agent. As 
compared to the previously tested nitrosourea drugs, this type of agent may be more effective and less 422
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toxic when administered concurrently with radio-
therapy. Looking ahead, the cost of this treatment 
may bring a considerable ﬁ  nancial burden to the 
Figure 1. 
health care providers of developing economies. To 
this end, until available tests can readily identify 
the methylation status of the MGMT promoters, 
not all patients should be referred for this therapy. 
Nevertheless, these studies are important 
contributions to the literature, supporting radio-
therapy combined with temozolomide as the new 
platform from which innovative regimens for 
treating malignant gliomas are explored.
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